Thai Drug Firms Face Uncertain Year In Sluggish Market
This article was originally published in PharmAsia News
Thailand's pharmaceutical industry is bracing for a possible slowdown in the growth of the market that grew by 18 percent last year. President Teera Chajnarodom, president of the Pharmaceutical Research and Manufacturers Association, said sales already are sluggish in the current quarter, primarily because hospital expenditures on medicines have slowed. He says he cannot predict the current year, but said the country has a new government and has not yet implemented an economic stimulus package. (Click here for more
You may also be interested in...
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
The US FDA’s Circulatory System Devices advisory panel will meet on 27 October to discuss the review of the premarket approval application of Neovasc’s Reducer device, which is intended to treat angina. See what Neovasc’s CEO Fred Colen said about it here.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.